Bristol Myers’ positive Phase 3 ALOFT-IPF result is an important development, but does it establish a commercially competitive IPF franchise? Our latest research examines whether admilparant can differentiate against an increasingly demanding competitive landscape, and why the investment case may be more compelling in progressive pulmonary fibrosis (PPF). We estimate combined peak sales of $800m across both indications, with significant questions remaining over the eventual commercial opportunity.